These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 19606707

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature.
    Cassaday RD, Malik JT, Chang JE.
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):289-92. PubMed ID: 21658658
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M, Domènech E, Marín L, Olivé A, Zabana Y, Cabré E, Gassull MA.
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Adalimumab for recurrent orbital myositis in Crohn's disease: report of a case with a 3-year follow-up.
    Hernández-Garfella ML, Gracia-García A, Cervera-Taulet E, García-Villanueva C, Montero-Hernández J.
    J Crohns Colitis; 2011 Jun; 5(3):265-6. PubMed ID: 21575896
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [The use of adalimumab in severe fistulising Crohn's disease].
    Bang UC, Nielsen AM.
    Ugeskr Laeger; 2008 Jun 16; 170(25):2256. PubMed ID: 18565318
    [Abstract] [Full Text] [Related]

  • 31. [Adalimumab therapy in Crohn's disdease].
    Baryshnikov EN, Lazebnik LB, Parfenov AI.
    Eksp Klin Gastroenterol; 2009 Jun 16; (5):92-8. PubMed ID: 20205331
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Fulminant Crohn's colitis: when only an antibody will do.
    Ng SC, Kamm MA.
    Inflamm Bowel Dis; 2007 Aug 16; 13(8):971-4. PubMed ID: 17427240
    [Abstract] [Full Text] [Related]

  • 34. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
    Hinojosa J, Borrás-Blasco J, Maroto N, Rosique-Robles JD, Alos R, Casterá ME.
    Ann Pharmacother; 2008 Jul 16; 42(7):1130-3. PubMed ID: 18492783
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A, Rocamora Durán V, Sapiña Camaró A, Royo Escosa V, Bosque López MJ.
    Gastroenterol Hepatol; 2011 Oct 16; 34(8):546-50. PubMed ID: 21665330
    [Abstract] [Full Text] [Related]

  • 37. Atypical mycobacteria: showerheads, anti-TNF therapy and Crohn's disease.
    Desai AA, Marks DJ.
    Expert Rev Clin Immunol; 2010 Sep 16; 6(5):695-9. PubMed ID: 20828275
    [No Abstract] [Full Text] [Related]

  • 38. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J, Pociello N, Varea V.
    J Crohns Colitis; 2010 Nov 16; 4(5):594-8. PubMed ID: 21122566
    [Abstract] [Full Text] [Related]

  • 39. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
    Van Assche G, Vermeire S, Ballet V, Gabriels F, Noman M, D'Haens G, Claessens C, Humblet E, Vande Casteele N, Gils A, Rutgeerts P.
    Gut; 2012 Feb 16; 61(2):229-34. PubMed ID: 21948942
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.